Literature DB >> 15539554

Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats.

Prasanth K Chelikani1, Alvin C Haver, Roger D Reidelberger.   

Abstract

Peptide YY (3-36) [PYY (3-36)] is postulated to act as a hormonal signal from the gut to the brain to inhibit food intake and gastric emptying. A mixed-nutrient meal produces a prolonged 2-3 h increase in plasma levels of both PYY (3-36) and PYY (1-36). We determined the dose-dependent effects of 3-h iv infusions of PYY (3-36) and PYY (1-36) (0.5-50 pmol.kg(-1).min(-1)) at dark onset on food intake in non-food-deprived rats. PYY (3-36) dose-dependently inhibited food intake: the minimal effective dose was 5 pmol.kg(-1).min(-1); the estimated potency (mean effective dose) and efficacy (maximal percent inhibition) were 15 pmol.kg(-1).min(-1) (2.6 nmol/kg) and 47%, respectively. PYY (1-36) was an order of magnitude less potent than PYY (3-36). Similar total doses of PYY (3-36) (0.9-30 nmol/kg) infused during the 15-min period just before dark onset also dose-dependently inhibited food intake, albeit with a lower potency and efficacy. Other experiments showed that PYY (3-36) inhibited food intake in sham-feeding rats and was more effective in reducing intake of a mixed-nutrient liquid diet than 15% aqueous sucrose. We conclude that: 1) iv infusions of PYY (3-36), which are more likely than ip injections to mimic postprandial increases in plasma PYY (3-36), potently inhibit food intake in a dose-dependent manner; 2) PYY (1-36) is an order of magnitude less potent than PYY (3-36); and 3) PYY (3-36) can inhibit food intake independently of its action to inhibit gastric emptying. It remains to be determined whether iv doses of PYY (3-36) that reproduce postprandial increases in plasma PYY (3-36) are sufficient to inhibit food intake.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539554     DOI: 10.1210/en.2004-1138

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  49 in total

Review 1.  Gut hormones: the future of obesity treatment?

Authors:  Anne K McGavigan; Kevin G Murphy
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

2.  Strategies for preventing type 2 diabetes: an update for clinicians.

Authors:  Kaivan Khavandi; Halima Amer; Bashar Ibrahim; Jack Brownrigg
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

Review 3.  Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism.

Authors:  Diego Perez-Tilve; Ruben Nogueiras; Federico Mallo; Stephen C Benoit; Matthias Tschoep
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 4.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 5.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Minireview: Gut peptides: targets for antiobesity drug development?

Authors:  Timothy H Moran; Megan J Dailey
Journal:  Endocrinology       Date:  2009-04-16       Impact factor: 4.736

Review 7.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 8.  The vagus nerve, food intake and obesity.

Authors:  Hans-Rudolf Berthoud
Journal:  Regul Pept       Date:  2008-03-25

Review 9.  Gastrointestinal hormones regulating appetite.

Authors:  Owais Chaudhri; Caroline Small; Steve Bloom
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

10.  Distribution of peripherally injected peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the CNS: enrichment in the area postrema.

Authors:  Yvan Dumont; Emmanuel Moyse; Alain Fournier; Rémi Quirion
Journal:  J Mol Neurosci       Date:  2007-09-18       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.